Talus Bio was co-founded in 2020 by Alex Federation (CEO) and Lindsay Pino (CTO) and currently has 16 employees. Dr. Federation received his PhD in chemical biology from Harvard University, and Dr. Pino received her PhD in genome sciences from the University of Washington. Together, they are the co-inventors of functional regulome proteomics. Talus Bio’s automated, highly scalable drug discovery engine discovers first-in-class small molecules capable of modulating previously undruggable transcription factors, optimizing them to achieve high potency and selectivity while minimizing toxicity. Our unique approaches are designed with breadth and depth in mind, measuring all possible transcription factors across thousands of samples. Data at scale with precision requires computing to match it. Our data science team applies machine learning approaches to process and mine our dataset for first-in-class TF modulators.